Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.

Nontuberculous mycobacteria (NTM) represent over 190 species and subspecies, some of which can produce disease in humans of all ages and can affect both pulmonary and extrapulmonary sites. This guideline focuses on pulmonary disease in adults (without cystic fibrosis or human immunodeficiency virus infection) caused by the most common NTM pathogens such as Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium xenopi among the slowly growing NTM and Mycobacterium abscessus among the rapidly growing NTM. A panel of experts was carefully selected by leading international respiratory medicine and infectious diseases societies (ATS, ERS, ESCMID, IDSA) and included specialists in pulmonary medicine, infectious diseases and clinical microbiology, laboratory medicine, and patient advocacy. Systematic reviews were conducted around each of 22 PICO (Population, Intervention, Comparator, Outcome) questions and the recommendations were formulated, written, and graded using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach. Thirty-one evidence-based recommendations about treatment of NTM pulmonary disease are provided. This guideline is intended for use by healthcare professionals who care for patients with NTM pulmonary disease, including specialists in infectious diseases and pulmonary diseases.

[1]  R. Wallace,,et al.  Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Young Kil Park,et al.  Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. , 2009, American journal of respiratory and critical care medicine.

[3]  J. Grosset,et al.  Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. , 2013, The Journal of antimicrobial chemotherapy.

[4]  A. LaMarca,et al.  A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. , 1996, The New England journal of medicine.

[5]  D. Addrizzo-Harris,et al.  Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease , 2016, American journal of respiratory and critical care medicine.

[6]  J. Hilden,et al.  Clarithromycin for 2 Weeks for Stable Coronary Heart Disease: 6-Year Follow-Up of the CLARICOR Randomized Trial and Updated Meta-Analysis of Antibiotics for Coronary Heart Disease , 2008, Cardiology.

[7]  R. Wallace,,et al.  Antimicrobial Susceptibility Testing, Drug Resistance Mechanisms, and Therapy of Infections with Nontuberculous Mycobacteria , 2012, Clinical Microbiology Reviews.

[8]  Robert Horsburgh,et al.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. , 2007, American journal of respiratory and critical care medicine.

[9]  R. Wallace,,et al.  Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  William A. Black,et al.  Assessment of Partial Sequencing of the 65-Kilodalton Heat Shock Protein Gene (hsp65) for Routine Identification of Mycobacterium Species Isolated from Clinical Sources , 2004, Journal of Clinical Microbiology.

[11]  C. Ki,et al.  Response to Switch from Intermittent Therapy to Daily Therapy for Refractory Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease , 2015, Antimicrobial Agents and Chemotherapy.

[12]  Chun-Yu Lin,et al.  Risk factors for microbiologic failure among Taiwanese adults with Mycobacterium abscessus complex pulmonary disease. , 2015, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[13]  Soo Hyun Lee,et al.  Macrolide treatment for Mycobacterium abscessus and Mycobacterium massiliense infection and inducible resistance. , 2012, American journal of respiratory and critical care medicine.

[14]  J. Gálvez,et al.  In vitro activity of linezolid, clarithromycin and moxifloxacin against clinical isolates of Mycobacterium kansasii. , 2005, The Journal of antimicrobial chemotherapy.

[15]  R. Wallace,,et al.  Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease. , 2015, American journal of respiratory and critical care medicine.

[16]  Markus Kostrzewa,et al.  Comparison of MALDI-TOF MS with HPLC and nucleic acid sequencing for the identification of Mycobacterium species in cultures using solid medium and broth. , 2014, American journal of clinical pathology.

[17]  C. Daley,et al.  Treatment of pulmonary nontuberculous mycobacterial infections: many questions remain. , 2014, Annals of the American Thoracic Society.

[18]  J. Gaillard,et al.  Assessment of Clarithromycin Susceptibility in Strains Belonging to the Mycobacterium abscessus Group by erm(41) and rrl Sequencing , 2010, Antimicrobial Agents and Chemotherapy.

[19]  G. Guyatt,et al.  GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. , 2011, Journal of clinical epidemiology.

[20]  P. Kao,et al.  Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series , 2007, BMC pulmonary medicine.

[21]  Yong Soo Choi,et al.  Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease , 2015, BMC Infectious Diseases.

[22]  S. Holland,et al.  Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement , 2018, European Respiratory Journal.

[23]  K. Rabe,et al.  Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review , 2018, Chest.

[24]  P. Jenkins,et al.  Pulmonary infection with mycobacterium xenopi: review of treatment and response. , 1984, Thorax.

[25]  D. van Soolingen,et al.  Utility of rpoB Gene Sequencing for Identification of Nontuberculous Mycobacteria in the Netherlands , 2014, Journal of Clinical Microbiology.

[26]  S. Rüsch-Gerdes,et al.  Multilocus Sequence Analysis and rpoB Sequencing of Mycobacterium abscessus (Sensu Lato) Strains , 2010, Journal of Clinical Microbiology.

[27]  C Scarparo,et al.  Meta-Analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without Solid Media, for Detection of Mycobacteria , 2004, Journal of Clinical Microbiology.

[28]  R. Wallace,,et al.  Results of operation in Mycobacterium avium-intracellulare lung disease. , 1998, The Annals of thoracic surgery.

[29]  D. Curran‐Everett,et al.  Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  F. Alcaide,et al.  Evaluation of the BACTEC MGIT 960 and the MB/BacT Systems for Recovery of Mycobacteria from Clinical Specimens and for Species Identification by DNA AccuProbe , 2000, Journal of Clinical Microbiology.

[31]  J. Ingen,et al.  Microbiological criteria in non-tuberculous mycobacteria pulmonary disease: a tool for diagnosis and epidemiology. , 2016, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[32]  D. van Soolingen,et al.  Mycobacterium xenopi Clinical Relevance and Determinants, the Netherlands , 2008, Emerging infectious diseases.

[33]  T. Shim,et al.  Outcomes in patients with Mycobacterium abscessus pulmonary disease treated with long-term injectable drugs. , 2011, Respiratory medicine.

[34]  John D. Mitchell,et al.  Lady Windermere revisited: treatment with thoracoscopic lobectomy/segmentectomy for right middle lobe and lingular bronchiectasis associated with non-tuberculous mycobacterial disease. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[35]  H. Horinouchi,et al.  Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. , 2006, The Annals of thoracic surgery.

[36]  J. Yim,et al.  Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  Gordon H Guyatt,et al.  GRADE guidelines: 2. Framing the question and deciding on important outcomes. , 2011, Journal of clinical epidemiology.

[38]  D. van Soolingen,et al.  Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands , 2009, Thorax.

[39]  R. Wallace,,et al.  The significance of Mycobacterium abscessus subspecies abscessus isolation during Mycobacterium avium complex lung disease therapy. , 2015, Chest.

[40]  S. Muro,et al.  Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[41]  R. Wallace,,et al.  A definition of the Mycobacterium avium complex for taxonomical and clinical purposes, a review. , 2018, International journal of systematic and evolutionary microbiology.

[42]  I. D. Johnston.  Mycobacterium xenopi infection and aspergilloma. , 1988, Tubercle.

[43]  P. Buijtels,et al.  Characterization of a novel variant of Mycobacterium chimaera. , 2012, Journal of medical microbiology.

[44]  K. Takahashi,et al.  [Usefulness of bronchoscopy for the diagnosis of atypical pulmonary mycobacteriosis]. , 1999, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases.

[45]  D. Hornick,et al.  Nontuberculous mycobacterial lung disease. Substantiation of a less aggressive approach. , 1988, Chest.

[46]  T. Betsuyaku,et al.  The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases , 2017, BMC Infectious Diseases.

[47]  Chang Ki Kim,et al.  Oral Macrolide Therapy Following Short-term Combination Antibiotic Treatment of Mycobacterium massiliense Lung Disease. , 2016, Chest.

[48]  Yong Soo Choi,et al.  Surgical Treatment of Pulmonary Diseases Due to Nontuberculous Mycobacteria , 2008, Journal of Korean medical science.

[49]  J. Singer,et al.  A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. , 1996, The New England journal of medicine.

[50]  F. Alcaide,et al.  Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease , 2009, European Respiratory Journal.

[51]  John D. Mitchell,et al.  Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  I. Pin,et al.  Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[53]  T. Marras,et al.  Comparison of the Spectrum of Radiologic and Clinical Manifestations of Pulmonary Disease Caused by Mycobacterium avium Complex and Mycobacterium xenopi , 2014, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[54]  Y. Obase,et al.  Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[55]  S. Conlan,et al.  Cohort Study of Molecular Identification and Typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii , 2009, Journal of Clinical Microbiology.

[56]  E. Böttger,et al.  Drug susceptibility distributions in slowly growing non-tuberculous mycobacteria using MGIT 960 TB eXiST. , 2013, International journal of medical microbiology : IJMM.

[57]  R. Wallace,,et al.  Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. , 1994, American journal of respiratory and critical care medicine.

[58]  Yong Soo Choi,et al.  Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease , 2016, Antimicrobial Agents and Chemotherapy.

[59]  D. Deshpande,et al.  Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium–intracellulare complex disease , 2017, The Journal of antimicrobial chemotherapy.

[60]  Y. Nakanishi,et al.  The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[61]  C. Ki,et al.  Clinical Characteristics and Treatment Outcomes of Patients with Macrolide-Resistant Mycobacterium massiliense Lung Disease , 2016, Antimicrobial Agents and Chemotherapy.

[62]  A. Niimi,et al.  Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[63]  R. Wallace,,et al.  Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus , 1996, Antimicrobial agents and chemotherapy.

[64]  A. Kurashima,et al.  Early pulmonary resection for localized Mycobacterium avium complex disease. , 1998, The Annals of thoracic surgery.

[65]  S. Shin,et al.  Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. , 2012, American journal of respiratory and critical care medicine.

[66]  T. Kanauchi,et al.  Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. , 2012, American journal of respiratory and critical care medicine.

[67]  S. Field,et al.  Long-term Follow-up of Mycobacterium avium Complex Lung Disease in Patients Treated With Regimens Including Clofazimine and/or Rifampin. , 2016, Chest.

[68]  J. Kwong,et al.  Pulmonary Nontuberculous Mycobacteria–Associated Deaths, Ontario, Canada, 2001–2013 , 2017, Emerging infectious diseases.

[69]  T. Betsuyaku,et al.  Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series , 2016, BMC Infectious Diseases.

[70]  R. Thomson,et al.  Safety of IV amikacin in the treatment of pulmonary non‐tuberculous mycobacterial disease , 2016, Respirology.

[71]  Michael K Gould,et al.  An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. , 2006, American journal of respiratory and critical care medicine.

[72]  R. Wallace,,et al.  Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. , 1996, The Journal of infectious diseases.

[73]  J. Yim,et al.  Treatment Outcomes of Mycobacterium avium Complex Lung Disease: A Systematic Review and Meta-analysis , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[74]  M. Iseman,et al.  Concomitant Use of Voriconazole and Rifabutin in a Patient with Multiple Infections , 2008, Pharmacotherapy.

[75]  M. Drancourt,et al.  rpoB-Based Identification of Nonpigmented and Late-Pigmenting Rapidly Growing Mycobacteria , 2003, Journal of Clinical Microbiology.

[76]  V. Katalinić-Jankovič,et al.  Mycobacterium xenopi pulmonary disease - epidemiology and clinical features in non-immunocompromised patients. , 2009, The Journal of infection.

[77]  Young Kil Park,et al.  Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. , 2011, American journal of respiratory and critical care medicine.

[78]  R. Wallace,,et al.  Rifampin-resistant Mycobacterium kansasii. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[79]  X. Beristain,et al.  Comparison of the Automated Nonradiometric Bactec MGIT 960 System with Löwenstein-Jensen, Coletsos, and Middlebrook 7H11 Solid Media for Recovery of Mycobacteria , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[80]  A. O'donnell,et al.  Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry , 2017, Chest.

[81]  H. Park,et al.  Clinical significance of a single isolation of pathogenic nontuberculous mycobacteria from sputum specimens. , 2013, Diagnostic microbiology and infectious disease.

[82]  P. Jenkins,et al.  Treatment of pulmonary infections caused by mycobacteria of the Mycobacterium avium-intracellulare complex. , 1981, Thorax.

[83]  R. Wallace,,et al.  Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. , 1998, The Journal of infectious diseases.

[84]  R. Yeates,et al.  Interaction between midazolam and clarithromycin: comparison with azithromycin. , 1996, International journal of clinical pharmacology and therapeutics.

[85]  D. van Soolingen,et al.  Re-analysis of 178 previously unidentifiable Mycobacterium isolates in the Netherlands in 1999-2007. , 2010 .

[86]  R. Wallace,,et al.  A Novel Gene, erm(41), Confers Inducible Macrolide Resistance to Clinical Isolates of Mycobacterium abscessus but Is Absent from Mycobacterium chelonae , 2008, Antimicrobial Agents and Chemotherapy.

[87]  R. Wallace,,et al.  Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. , 2005, American journal of respiratory and critical care medicine.

[88]  D. Deshpande,et al.  Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence , 2017, Antimicrobial Agents and Chemotherapy.

[89]  C.-C. Shu,et al.  Factors associated with subsequent nontuberculous mycobacterial lung disease in patients with a single sputum isolate on initial examination. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[90]  P. Coll,et al.  Treatment of pulmonary disease caused by Mycobacterium kansasii: results of 18 vs 12 months' chemotherapy. , 1995, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[91]  A. Quittner,et al.  Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop Report. , 2016, Annals of the American Thoracic Society.

[92]  D. van Soolingen,et al.  Clinical relevance of Mycobacterium chelonae-abscessus group isolation in 95 patients. , 2009, The Journal of infection.

[93]  C. Benson,et al.  Clarithromycin Therapy for Bacteremic Mycobacterium avium Complex Disease , 1994, Annals of Internal Medicine.

[94]  W. Ludwig,et al.  Differentiation of Phylogenetically Related Slowly Growing Mycobacteria Based on 16S-23S rRNA Gene Internal Transcribed Spacer Sequences , 1998, Journal of Clinical Microbiology.

[95]  S. Garay,et al.  Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. , 2006, American journal of respiratory and critical care medicine.

[96]  R. Wallace,,et al.  Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[97]  K. Matsuura,et al.  Long-term radiographic outcome of nodular bronchiectatic Mycobacterium avium complex pulmonary disease. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[98]  M. Tsukamura.  Diagnosis of disease caused by Mycobacterium avium complex. , 1991, Chest.

[99]  C. Ki,et al.  Intermittent Antibiotic Therapy for Recurrent Nodular Bronchiectatic Mycobacterium avium Complex Lung Disease , 2017, Antimicrobial Agents and Chemotherapy.

[100]  C. Horsburgh,et al.  A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[101]  D. Hansell,et al.  Mycobacterium avium complex infection in non‐cystic fibrosis bronchiectasis , 2014, Respirology.

[102]  R. Wallace,,et al.  Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system , 1992, Antimicrobial Agents and Chemotherapy.

[103]  S. Shin,et al.  Peak Plasma Concentration of Azithromycin and Treatment Responses in Mycobacterium avium Complex Lung Disease , 2016, Antimicrobial Agents and Chemotherapy.

[104]  R. Chaisson,et al.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[105]  R. Wallace,,et al.  Repeat positive cultures in Mycobacterium intracellulare lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis. , 2002, The Journal of infectious diseases.

[106]  F. Alcaide,et al.  How to: identify non-tuberculous Mycobacterium species using MALDI-TOF mass spectrometry. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[107]  C. Peloquin,et al.  Tuberculosis pharmacotherapy: strategies to optimize patient care , 2009, Expert opinion on pharmacotherapy.

[108]  W. Johanson,et al.  Response to chemotherapy of pulmonary infection due to Mycobacterium kansasii. , 1975, The American review of respiratory disease.

[109]  K. Winthrop,et al.  Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012. , 2015, Annals of the American Thoracic Society.

[110]  G. Bloemberg,et al.  Acquisition of clarithromycin resistance mutations in the 23S rRNA gene of Mycobacterium abscessus in the presence of inducible erm(41). , 2012, The Journal of antimicrobial chemotherapy.

[111]  J. Raleigh,et al.  Treatment of pulmonary disease due to Mycobacterium kansasii: recent experience with rifampin. , 1981, Reviews of infectious diseases.

[112]  K. Manickam,et al.  Evaluation of BacT/Alert 3D Automated Unit for Detection of Nontuberculous Mycobacteria Requiring Incubation at 30°C for Optimal Growth , 2011, Journal of Clinical Microbiology.

[113]  E. Y. Kim,et al.  Factors associated with quality of life measured by EQ-5D in patients with nontuberculous mycobacterial pulmonary disease , 2014, Quality of Life Research.

[114]  T. Hoffmann,et al.  Adverse events in people taking macrolide antibiotics versus placebo for any indication. , 2015, The Cochrane database of systematic reviews.

[115]  S. Spencer,et al.  Macrolide antibiotics for bronchiectasis. , 2018, The Cochrane database of systematic reviews.

[116]  B. Berçot,et al.  Standardized interpretation of antibiotic susceptibility testing and resistance genotyping for Mycobacterium abscessus with regard to subspecies and erm41 sequevar. , 2016, The Journal of antimicrobial chemotherapy.

[117]  E. Tortoli,et al.  Commercial DNA Probes for Mycobacteria Incorrectly Identify a Number of Less Frequently Encountered Species , 2009, Journal of Clinical Microbiology.

[118]  Mary Ann Blosky,et al.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. , 2010, American journal of respiratory and critical care medicine.

[119]  G. Bloemberg,et al.  Detection and Identification of Mycobacterium spp. in Clinical Specimens by Combining the Roche Cobas Amplicor Mycobacterium tuberculosis Assay with Mycobacterium Genus Detection and Nucleic Acid Sequencing , 2010, Journal of Clinical Microbiology.

[120]  M. Kramer,et al.  Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. , 2006, Chest.

[121]  David Rind,et al.  GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. , 2013, Journal of clinical epidemiology.

[122]  D. R. Prevots,et al.  Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. , 2015, Clinics in chest medicine.

[123]  Chin-Chou Wang,et al.  Nontuberculous mycobacterial lung disease in southern Taiwan. , 2009, Chang Gung medical journal.

[124]  T. Kanauchi,et al.  Retrospective study of the predictors of mortality and radiographic deterioration in 782 patients with nodular/bronchiectatic Mycobacterium avium complex lung disease , 2015, BMJ Open.

[125]  T. Marras,et al.  Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010 , 2013, Emerging infectious diseases.

[126]  William Girard,et al.  Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. , 2006, American journal of respiratory and critical care medicine.

[127]  H. Sørensen,et al.  Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. , 2010, American journal of respiratory and critical care medicine.

[128]  A. Niimi,et al.  Yield of computed tomography and bronchoscopy for the diagnosis of Mycobacterium avium complex pulmonary disease. , 1997, American journal of respiratory and critical care medicine.

[129]  T. Marras,et al.  Pulmonary Mycobacterium xenopi infection in non-HIV-infected patients: a systematic review. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[130]  K. Lee,et al.  Nodular bronchiectatic Mycobacterium avium complex pulmonary disease. Natural course on serial computed tomographic scans. , 2013, Annals of the American Thoracic Society.

[131]  Yong Soo Choi,et al.  Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[132]  S. Field,et al.  Mycobacterium avium complex pulmonary disease in patients without HIV infection. , 2004, Chest.

[133]  D. van Soolingen,et al.  Resistance mechanisms and drug susceptibility testing of nontuberculous mycobacteria. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[134]  R. Wallace,,et al.  Drug intolerance to high-dose clarithromycin among elderly patients. , 1993, Diagnostic microbiology and infectious disease.

[135]  C. Daley,et al.  Improvement in Quality of Life after Therapy for Mycobacterium abscessus Group Lung Infection. A Prospective Cohort Study. , 2016, Annals of the American Thoracic Society.

[136]  R. Diel,et al.  Microbiological and Clinical Outcomes of Treating Non‐Mycobacterium Avium Complex Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta‐Analysis , 2017, Chest.

[137]  J. J. Lee,et al.  Comparative evaluation of the BACTEC MGIT 960 system with solid medium for isolation of mycobacteria. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[138]  W. Hoefsloot,et al.  Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort. , 2017, Respiratory medicine.

[139]  E. Cambau,et al.  Comparison of Saramis 4.12 and IVD 3.0 Vitek MS Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Identification of Mycobacteria from Solid and Liquid Culture Media , 2017, Journal of Clinical Microbiology.

[140]  N. Miyashita,et al.  Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates , 2006, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[141]  P. Cegielski,et al.  Early results (at 6 months) with intermittent clarithromycin-including regimens for lung disease due to Mycobacterium avium complex. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[142]  D. van Soolingen,et al.  Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance. , 2013, International journal of antimicrobial agents.

[143]  A. D. de Jong,et al.  Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry Fails To Identify Nontuberculous Mycobacteria from Primary Cultures of Respiratory Samples , 2016, Journal of Clinical Microbiology.

[144]  M. Smith,et al.  Clinical review of pulmonary disease caused by Mycobacterium xenopi. , 1983, Thorax.

[145]  C. Kemper,et al.  Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. , 1996, The New England journal of medicine.

[146]  A. Safdar.  Aerosolized amikacin in patients with difficult-to-treat pulmonary nontuberculous mycobacteriosis , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[147]  R. Wallace,,et al.  Clinical features of pulmonary disease caused by rapidly growing mycobacteria. An analysis of 154 patients. , 1993, The American review of respiratory disease.

[148]  P. Jenkins,et al.  Pulmonary disease caused by Mycobacterium xenopi in HIV-negative patients: five year follow-up of patients receiving standardised treatment. , 2003, Respiratory medicine.

[149]  A. Dujon,et al.  Pulmonary resection for Mycobacterium xenopi pulmonary infection. , 2001, Annals of Thoracic Surgery.

[150]  K. Eisenach,et al.  Comparison of two concentrations of NALC-NaOH for decontamination of sputum for mycobacterial culture. , 2009, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[151]  A. Dingemans,et al.  Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study. , 2015, Respiratory medicine.

[152]  R. Wallace,,et al.  Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[153]  Y. Ikedo.  The significance of bronchoscopy for the diagnosis of Mycobacterium avium complex (MAC) pulmonary disease. , 2001, The Kurume medical journal.

[154]  John D. Mitchell,et al.  Anatomic lung resection for nontuberculous mycobacterial disease. , 2008, The Annals of thoracic surgery.

[155]  N. Veziris,et al.  Selection of Resistance to Clarithromycin in Mycobacterium abscessus Subspecies , 2016, Antimicrobial Agents and Chemotherapy.

[156]  Mikio Oka,et al.  A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. , 2007, Respiratory medicine.

[157]  C. Ki,et al.  Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. , 2015, American journal of respiratory and critical care medicine.

[158]  S. Ahn,et al.  Chemotherapy for pulmonary disease due to Mycobacterium kansasii: efficacies of some individual drugs. , 1981, Reviews of infectious diseases.

[159]  S. Field,et al.  Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. , 2003, Chest.

[160]  J. Gutiérrez,et al.  Comparative evaluation of three culture methods for the isolation of mycobacteria from clinical samples. , 2009, Journal of microbiology and biotechnology.

[161]  A. Akram,et al.  Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies , 2013, BMJ.

[162]  T. Jagielski,et al.  Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii , 2018, Antimicrobial Agents and Chemotherapy.

[163]  K. Chida,et al.  Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. , 2014, Annals of the American Thoracic Society.

[164]  S. Rüsch-Gerdes,et al.  Use of the BACTEC Mycobacteria Growth Indicator Tube 960 Automated System for Recovery of Mycobacteria from 9,558 Extrapulmonary Specimens, Including Urine Samples , 2006, Journal of Clinical Microbiology.

[165]  F. Alcaide,et al.  Comparative In Vitro Activities of Linezolid, Telithromycin, Clarithromycin, Levofloxacin, Moxifloxacin, and Four Conventional Antimycobacterial Drugs against Mycobacterium kansasii , 2004, Antimicrobial Agents and Chemotherapy.

[166]  H. Aizawa,et al.  Usefulness of bronchial lavage for the diagnosis of pulmonary disease caused by Mycobacterium avium-intracellulare complex (MAC) infection , 2003, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[167]  R. Wallace,,et al.  In Vitro Activity of Amikacin against Isolates of Mycobacterium avium Complex with Proposed MIC Breakpoints and Finding of a 16S rRNA Gene Mutation in Treated Isolates , 2013, Journal of Clinical Microbiology.

[168]  S. Ahn,et al.  Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. , 1983, The American review of respiratory disease.

[169]  C. Daley,et al.  In Vitro Synergy between Clofazimine and Amikacin in Treatment of Nontuberculous Mycobacterial Disease , 2012, Antimicrobial Agents and Chemotherapy.

[170]  T. Betsuyaku,et al.  Macrolide-Resistant Mycobacterium avium Complex Lung Disease: Analysis of 102 Consecutive Cases. , 2016, Annals of the American Thoracic Society.

[171]  R. Wallace,,et al.  Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare , 1994, Antimicrobial Agents and Chemotherapy.

[172]  R. Wallace,,et al.  Clarithromycin regimens for pulmonary Mycobacterium avium complex. The first 50 patients. , 1996, American journal of respiratory and critical care medicine.

[173]  D. van Soolingen,et al.  Time-kill kinetics of slowly growing mycobacteria common in pulmonary disease. , 2015, The Journal of antimicrobial chemotherapy.

[174]  J. Pasipanodya,et al.  Rapid Drug Tolerance and Dramatic Sterilizing Effect of Moxifloxacin Monotherapy in a Novel Hollow-Fiber Model of Intracellular Mycobacterium kansasii Disease , 2015, Antimicrobial Agents and Chemotherapy.

[175]  Po-Yu Liu,et al.  Clinical outcome of Mycobacterium abscessus infection and antimicrobial susceptibility testing. , 2010, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[176]  D. van Soolingen,et al.  The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[177]  T. Iwamoto,et al.  Clinical and Microbiological Differences between Mycobacterium abscessus and Mycobacterium massiliense Lung Diseases , 2012, Journal of Clinical Microbiology.

[178]  T. Hanaoka,et al.  Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. , 2002, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[179]  D. Cohn,et al.  A 62-Dose, 6-Month Therapy for Pulmonary and Extrapulmonary Tuberculosis: A Twice-Weekly, Directly Observed, and Cost-Effective Regimen , 1990 .

[180]  S. Niemann,et al.  Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacteriumabscessus subsp. bolletii and designation of Mycobacteriumabscessus subsp. massiliense comb. nov. , 2016, International journal of systematic and evolutionary microbiology.

[181]  A. Pollack,et al.  HUMAN INFECTION WITH ATYPICAL ACID-FAST ORGANISMS , 1953 .

[182]  E. Rubinstein.  Comparative safety of the different macrolides. , 2001, International journal of antimicrobial agents.

[183]  J. Yim,et al.  Amikacin Liposome Inhalation Suspension for Treatment‐Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open‐Label, Randomized Study , 2018, American journal of respiratory and critical care medicine.

[184]  P. Kao,et al.  Mycobacterium avium-intracellulare pulmonary infection in HIV-negative patients without preexisting lung disease: diagnostic and management limitations. , 1999, Chest.

[185]  D. van Soolingen,et al.  Are phylogenetic position, virulence, drug susceptibility and in vivo response to treatment in mycobacteria interrelated? , 2012, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[186]  Chong-Jen Yu,et al.  Clinical Characteristics and Prognosis of Nontuberculous Mycobacterial Lung Disease with Different Radiographic Patterns , 2011, Lung.

[187]  P. Polgreen,et al.  Treatment of Mycobacterium abscessus Infection , 2016, Emerging infectious diseases.

[188]  C. Daley,et al.  The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. , 2012, American journal of respiratory and critical care medicine.

[189]  R. Wallace,,et al.  Sulfonamide-containing regimens for disease caused by rifampin-resistant Mycobacterium kansasii. , 2015, The American review of respiratory disease.

[190]  T. Shim,et al.  Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course , 2017, European Respiratory Journal.

[191]  O. Kwon,et al.  Amikacin Inhalation as Salvage Therapy for Refractory Nontuberculous Mycobacterial Lung Disease , 2018, Antimicrobial Agents and Chemotherapy.

[192]  T. Tupasi,et al.  Rapid and improved recovery rate of Mycobacterium tuberculosis in Mycobacteria Growth Indicator Tube combined with solid Löwenstein Jensen medium. , 1997, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[193]  G. Gilbert,et al.  Clinical evaluation of the Mycobacteria Growth Indicator Tube (MGIT) compared with radiometric (Bactec) and solid media for isolation of Mycobacterium species. , 1998, Journal of medical microbiology.

[194]  T. Marras,et al.  Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. , 2011, Respiratory medicine.

[195]  N. Takahashi,et al.  Pneumonectomy for nontuberculous mycobacterial infections. , 2004, The Annals of thoracic surgery.

[196]  Tanya S. Glaser,et al.  Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. , 2014, Annals of the American Thoracic Society.

[197]  J. Alffenaar,et al.  Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections. , 2013, International journal of antimicrobial agents.

[198]  G. Bloemberg,et al.  Diagnostic Molecular Mycobacteriology in Regions With Low Tuberculosis Endemicity: Combining Real-time PCR Assays for Detection of Multiple Mycobacterial Pathogens With Line Probe Assays for Identification of Resistance Mutations , 2016, EBioMedicine.

[199]  R. Wallace,,et al.  Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. , 2014, Chest.

[200]  B. Dautzenberg,et al.  Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. , 1991, The American review of respiratory disease.

[201]  T. Shim,et al.  A shorter treatment duration may be sufficient for patients with Mycobacterium massiliense lung disease than with Mycobacterium abscessus lung disease. , 2014, Respiratory medicine.

[202]  R. Wallace,,et al.  Azithromycin activity against Mycobacterium avium complex lung disease in patients who were not infected with human immunodeficiency virus. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[203]  Paige L. Williams,et al.  A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[204]  C. Ki,et al.  Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype , 2017, European Respiratory Journal.

[205]  J. Dai,et al.  Meta-analysis of macrolide maintenance therapy for prevention of disease exacerbations in patients with noncystic fibrosis bronchiectasis , 2019, Medicine.

[206]  J. Kadota,et al.  The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study. , 2017, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[207]  Yazdan,et al.  Mycobacterium xenopi pulmonary infections: a multicentric retrospective study of 136 cases in north-east France , 2008, Thorax.

[208]  W. Dunne,et al.  Comparison of the Automated Mycobacteria Growth Indicator Tube System (BACTEC 960/MGIT) with Löwenstein-Jensen medium for recovery of mycobacteria from clinical specimens. , 2002, American journal of clinical pathology.

[209]  R. Wallace,,et al.  A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. , 1998, The Journal of infectious diseases.

[210]  D. van Soolingen,et al.  Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin , 2015, Antimicrobial Agents and Chemotherapy.

[211]  C. Kemper,et al.  Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans? , 1996, The Journal of infectious diseases.

[212]  J. Robert,et al.  Efficacies of Clarithromycin Regimens against Mycobacterium xenopi in Mice , 2001, Antimicrobial Agents and Chemotherapy.

[213]  D. van Soolingen,et al.  Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[214]  R. Prescott,et al.  Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy , 2008, Thorax.

[215]  F. Lescure,et al.  Non-tuberculous mycobacteria pulmonary infection: management and follow-up of 31 infected patients. , 2007, The Journal of infection.

[216]  J. Philley,et al.  Treatment of slowly growing mycobacteria. , 2015, Clinics in chest medicine.

[217]  R. Wallace,,et al.  Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes , 2011 .